Multicenter prospective phase II study of decitabine priming with low-dose idarubicin, cytarabine, and G-CSF in children with refractory or relapsed acute myeloid leukemia

Key Points

• This study aims to assess the efficacy of a treatment regimen combining decitabine and low-dose idarubicin for pediatric patients with refractory or relapsed acute myeloid leukemia.
• Conducted as a multicenter, prospective Phase II trial
• Involved 101 evaluable pediatric patients with relapsed/refractory acute myeloid leukemia
• Administered decitabine with low-dose idarubicin, cytarabine, and G-CSF
• Demonstrated a response in a significant proportion of patients
• Highlighted potential improvement in treatment outcomes for this vulnerable population
• Detailed specific response rates and survival metrics in the full study outcomes